Thrombolysis In Cerebral Infarction grading — assessing angiographic reperfusion after mechanical thrombectomy for large-vessel occlusion stroke
The Thrombolysis In Cerebral Infarction (TICI) scale grades the angiographic result of recanalization therapy for acute ischemic stroke caused by large-vessel occlusion (LVO). TICI 0 is the baseline: a thrombus completely obstructs the vessel lumen, and no contrast passes beyond the occlusion on digital subtraction angiography (DSA). Understanding this starting point — and why it is so lethal to brain tissue — is the foundation for interpreting every grade above it.
The TICI scale is a direct adaptation of the Thrombolysis In Myocardial Infarction (TIMI) scale used in cardiology since the 1980s to describe coronary artery reperfusion after thrombolysis or PCI. Higashida and colleagues (Stroke, 2003) proposed a cerebral analogue because stroke interventionalists needed a standardized, reproducible way to communicate angiographic outcome after intra-arterial thrombolysis and, later, mechanical thrombectomy.
TICI grades range from 0 (no perfusion) to 3 (complete perfusion), assessed on the final digital subtraction angiography run at the end of the endovascular procedure. Unlike infarct volume on follow-up imaging (which reflects the interaction of occlusion time, collateral status, and reperfusion together), TICI grade is a pure, immediate readout of the mechanical result achieved in the angiography suite — did the vessel open, and did blood actually reach the tissue it supplies?
When a thrombus completely occludes a proximal vessel (internal carotid artery terminus, M1/M2 segment of the middle cerebral artery, or basilar artery), the tissue it supplies loses its primary blood source instantly. Some residual perfusion may arrive through pial collateral vessels — small anastomotic channels connecting adjacent vascular territories — but in TICI 0, by definition, no contrast crosses the occlusion on the injected vessel itself.
Cerebral blood flow (CBF) below approximately 10 mL/100g/min triggers irreversible infarction within minutes (the ischemic core); flow between roughly 10–20 mL/100g/min defines the "penumbra" — tissue that is functionally silent but still structurally viable, salvageable if flow is restored quickly. The core expands into the penumbra at a rate strongly dependent on collateral robustness: in poor collateralizers, the entire penumbra can infarct within 1–2 hours; in "good collateralizers," salvageable tissue may persist for 12–24 hours or more. This variability is precisely why door-to-recanalization time and final TICI grade both independently predict outcome.
A TICI 0 result at the end of a thrombectomy attempt is not a "grade" so much as a treatment failure — it means the procedure did not restore any flow to the ischemic territory. In trial cohorts, patients left at TICI 0/1 have functional independence rates similar to, or only marginally better than, natural history without any endovascular intervention.
Intravenous alteplase (tPA), the mainstay pharmacological thrombolytic, recanalizes proximal large-vessel occlusions in only about 10–30% of cases — the clot burden is often too large and too fibrin/platelet-dense for a systemic enzyme to dissolve within the therapeutic window. This left a large population of LVO stroke patients with persistently occluded vessels (TICI 0) despite "treatment."
The 2015 wave of positive endovascular trials (MR CLEAN, ESCAPE, SWIFT PRIME, EXTEND-IA, REVASCAT) demonstrated that mechanical thrombectomy — using stent retrievers or aspiration catheters to physically extract the clot — could convert the majority of TICI 0 occlusions to TICI 2b or better, and that doing so translated directly into improved 90-day functional outcomes. TICI grading became the primary angiographic endpoint reported in every one of these trials, cementing its role as the universal language of endovascular stroke therapy.
TICI 1 describes a subtle but clinically important intermediate state: contrast passes beyond the point of occlusion, proving that the vessel is no longer completely sealed, yet the distal vascular territory still fails to opacify. The thrombus has been partially disrupted or a thin channel has recanalized, but the amount of flow reaching the capillary bed is functionally negligible.
The TICI 0/1 boundary and the TICI 1/2a boundary are both defined by whether the distal capillary bed opacifies, not merely by whether any contrast crosses the occlusion:
• TICI 0: no contrast passes the occlusion point at all. • TICI 1: contrast passes the occlusion (a "trickle" or thin jet is visible immediately distal to the clot) but antegrade flow is too slow or too limited in caliber to reach and fill the distal arterial branches and capillary bed within the timeframe of the angiographic run. • TICI 2a: contrast now demonstrably opacifies part (less than half) of the previously occluded distal territory.
This distinction matters because it separates "the catheter/device dislodged or fragmented the thrombus slightly" from "flow is actually reaching brain tissue." A operator may see contrast squeeze past a clot on live fluoroscopy and be tempted to consider the case improved — but if the distal territory never lights up, the tissue is still not being perfused, and by convention this remains TICI 1, not a treatment success.
Multiple pooled analyses (including the HERMES collaboration, individual patient data from the five 2015 pivotal trials) consistently show that TICI 0 and TICI 1 outcomes cluster together and are both markedly worse than TICI 2b or above. The minimal flow of TICI 1 is not enough to meaningfully slow core growth or rescue penumbral tissue — capillary perfusion pressure and oxygen/glucose delivery both remain far below the threshold required for neuronal survival.
Operationally, when the final angiographic run shows TICI 1, the interventional team is expected to continue the procedure: attempt an additional device pass, switch technique (e.g., from stent retriever to aspiration, or add a balloon-guide catheter for proximal flow arrest), or reassess for an underlying etiology such as a tandem cervical occlusion or severe intracranial stenosis that is limiting flow even after the visible clot has been addressed.
A trickle of flow at the end of a thrombectomy attempt can have several causes besides residual native thrombus:
• Distal embolization: thrombus fragments dislodged during device retrieval can migrate into smaller, previously patent distal branches, creating new occlusions even as the primary occlusion site opens. • Catheter-induced vasospasm: mechanical irritation from repeated device passes can cause reversible narrowing of the parent vessel, mimicking residual stenosis on the angiogram; this typically responds to intra-arterial verapamil or nicardipine and time. • Retained clot fragments in the target vessel with a thin residual channel: the classic TICI 1 picture, usually requiring further mechanical extraction.
Distinguishing between these is important because the corrective action differs — vasospasm calls for a vasodilator, distal emboli call for further retrieval in the newly occluded branch, and residual native thrombus calls for another pass at the original site.
TICI 2a and 2b both describe partial filling of the distal vascular territory, split at the clinically decisive threshold of 50%. This single boundary is arguably the most important cut point in all of endovascular stroke therapy: TICI 2b or better is the conventional definition of "successful reperfusion," the primary angiographic endpoint reported in every major thrombectomy trial and the trigger for deciding whether a procedure is finished.
Early TICI literature and the pivotal 2015 endovascular trials converged on TICI 2b/3 as the definition of angiographic success because outcome data showed a clear inflection at roughly the halfway point of territory reperfusion. Below 50% filling, enough of the vascular bed typically remains under-perfused that infarct growth continues in a clinically meaningful portion of the affected region. At or above 50% filling, enough eloquent and non-eloquent tissue is rescued that the population-level probability of a good functional outcome (modified Rankin Scale 0–2 at 90 days) rises sharply.
This is a population-derived threshold, not a hard biological switch for any individual patient — a patient with TICI 2a in a small, non-eloquent territory may do well, while a patient with TICI 2b sparing only redundant tissue may not. Nonetheless, as a trial endpoint and as a bedside decision rule ("is this procedure finished?"), the ≥2b threshold has proven remarkably robust and is now embedded in essentially every stroke thrombectomy guideline worldwide.
In practice, operators estimate the percentage of the pre-treatment occluded territory that opacifies on the final DSA run, comparing it against the baseline occlusion map from the initial diagnostic angiogram:
• TICI 2a: antegrade reperfusion of less than half of the previously occluded target artery territory (e.g., only the superior division of the MCA fills, while the inferior division remains dark). • TICI 2b: antegrade reperfusion of half or more of the previously occluded target artery territory, but with a persisting, visible filling defect somewhere in the distal branches — it is "mostly there" but incomplete.
This estimation is inherently somewhat subjective, which has historically driven inter-rater variability in TICI grading. Core-lab adjudication (independent expert review of angiographic runs, blinded to clinical outcome) is now standard in clinical trials specifically to reduce this variability, and structured training materials — visual atlases comparing side-by-side examples of 2a vs. 2b — are used to calibrate raters.
Modern thrombectomy technique combines stent retrievers (which trap and drag the clot into the guide catheter) with large-bore aspiration catheters (which apply direct suction, either alone — "a direct aspiration first pass technique," ADAPT — or in combination with a stent retriever — "Solumbra" or combined techniques). Adjuncts such as balloon-guide catheters, which occlude proximal antegrade flow and even reverse flow during clot retrieval, reduce the risk of clot fragmentation and distal embolization that would otherwise convert a potential TICI 3 into a TICI 2b or lower.
The "first-pass effect" (FPE) — achieving TICI 2b or better on the very first device pass — is an increasingly emphasized quality metric, because each additional pass adds procedure time, raises the risk of vessel injury and distal emboli, and is independently associated with worse outcomes even when the eventual final TICI grade is the same. A high first-pass ≥2b rate reflects both device technology and operator technique, and many centers now track it as a core performance indicator alongside final TICI grade.
TICI 2c was added to the original 0–3 scale in the 2013 consensus statement on angiographic revascularization grading (Zaidat et al., Stroke) to capture a common and clinically distinct final result: near-complete filling of the distal territory, but with either slow flow or a trivial, peripheral filling defect that keeps the result just short of a true TICI 3. This "extended TICI" or "mTICI" grade sits between 2b and 3 and carries an outcome profile closer to — and in some analyses statistically indistinguishable from — complete perfusion.
In the original Higashida 2003 scale, any near-complete result with a trivial residual defect or transit delay was still forced into either "TICI 2b" (if raters focused on the imperfection) or "TICI 3" (if raters focused on the overwhelming majority of filled territory). This binary forcing created substantial inter-rater disagreement precisely at the high-performance end of the scale — exactly where trial outcome differences were most likely to be diluted by miscategorization.
The 2013 multidisciplinary consensus panel (representing the American Society of Neuroradiology, Society of NeuroInterventional Surgery, and other stakeholder societies) formalized TICI 2c as its own grade: complete or near-complete filling of the expected distal territory, with either (a) a slight, peripheral, non-flow-limiting filling defect in a distal branch, or (b) delayed but eventually complete filling ("slow flow") compared to the contralateral or a reference vessel. This modified scale is often referred to as "mTICI" (modified/extended TICI) in the interventional literature and is now the version used in essentially all contemporary thrombectomy trials.
Slow antegrade flow despite a fully open proximal vessel is a recognized angiographic pattern following thrombectomy, sometimes called incomplete microvascular reperfusion or a component of the broader "no-reflow" phenomenon first described in cardiac reperfusion literature. Even after the large-vessel occlusion is mechanically cleared, downstream microcirculation can remain compromised due to:
• Microthrombi and platelet-fibrin debris showered into distal capillaries during clot manipulation • Endothelial swelling and pericyte constriction triggered by the ischemic insult itself, narrowing capillary lumens • Loss of normal cerebral autoregulation in ischemic tissue, producing inconsistent perfusion pressure
A TICI 2c result — technically successful large-vessel recanalization with residual sluggish distal flow — is the angiographic signature of this partial microvascular compromise. It generally still represents an excellent outcome relative to lower grades, but it is a useful reminder that "the big vessel is open" and "the tissue is being adequately perfused" are related but not identical concepts.
Several post-hoc analyses of pooled trial data show that patients achieving TICI 2c have 90-day functional outcomes statistically much closer to TICI 3 than to TICI 2b, supporting the clinical validity of treating 2c as a near-complete rather than merely "improved partial" result — and reinforcing why operators are encouraged to keep working toward 2c/3 rather than stopping as soon as the 2b threshold is crossed, when it is safe to do so.
Because TICI 2c already exceeds the ≥2b "successful reperfusion" threshold and carries a strong outcome profile, interventionalists must weigh the marginal benefit of further device passes (converting 2c to 3) against the cumulative procedural risk of continued manipulation — vessel dissection, perforation, additional distal emboli, and prolonged procedure time, each of which can erode the very benefit being pursued.
In general, once TICI 2c is achieved with a stable, non-flow-limiting residual defect, many operators elect to stop, particularly if the case has already required multiple passes or shows any sign of vessel wall injury. This is a judgment call weighed against factors such as total ischemic time already elapsed, collateral status, and whether the residual defect is in an eloquent versus non-eloquent territory.
TICI 3 represents the best possible angiographic result: full antegrade flow fills the entire distal vascular territory at normal, brisk velocity, with no filling defects anywhere and no residual delay compared to unaffected vessels. It is the endpoint every thrombectomy procedure aims for, and it is associated with the highest rates of functional independence at 90 days of any TICI grade — though even complete recanalization does not guarantee a good outcome, because tissue already infarcted before treatment cannot be reperfused back to life.
TICI 3 requires that the entire vascular territory that was occluded at baseline now fills completely, at a rate and pattern indistinguishable from a normal, non-diseased vessel — no residual filling defect, no perceptible delay in the venous phase relative to the contralateral hemisphere, and no visible stagnant contrast column anywhere in the distal branches.
Achieving TICI 3 typically requires that the entire thrombus burden be removed in one coherent extraction (or a small number of clean passes) without fragmentation, and that no new distal emboli have been created in branches that were previously normal. Balloon-guide catheter flow arrest/reversal during retrieval, careful device selection matched to clot composition (friable red-cell-rich clot favors aspiration; organized fibrin-rich clot favors stent retriever engagement), and minimizing total pass count are all technique-level factors associated with higher rates of TICI 3.
Complete reperfusion restores blood flow, but it cannot reverse tissue that has already progressed to irreversible infarction (the ischemic core) before the vessel was opened. This is the central caveat behind the concept of "futile recanalization": a meaningful fraction of patients — commonly cited in the range of roughly 30–50% across various cohorts — achieve TICI 2b/3 (or even TICI 3) yet still experience a poor 90-day functional outcome (mRS 3–6), typically because:
• The pre-treatment ischemic core was already large (poor patient selection on baseline imaging) • Time from symptom onset to recanalization was long, allowing core growth to consume most of the penumbra • Reperfusion injury occurred — paradoxical tissue damage from the sudden restoration of blood flow and oxygen to vulnerable, already-injured tissue, including hemorrhagic transformation • Poor collateral status meant the penumbra had already been exhausted despite a nominally "on time" intervention
This is why baseline imaging selection (CT perfusion, MR-DWI, or ASPECTS scoring on non-contrast CT) and time-to-treatment metrics remain just as important as the technical angiographic result — TICI grade measures whether the plumbing was fixed, not whether the house had already burned down.
The clinical trials that established thrombectomy as standard of care (2015 onward) succeeded in large part because they combined rigorous baseline imaging selection with fast time-to-treatment protocols and skilled achievement of high TICI grades — no single one of these three factors alone was sufficient to produce the dramatic outcome benefits observed.
Because TICI grading is assessed immediately, on the angiography table, it provides investigators with a fast, procedure-level readout that precedes clinical outcome by weeks — making it the standard primary or key secondary angiographic endpoint in essentially every modern thrombectomy trial (MR CLEAN, SWIFT PRIME, DAWN, DEFUSE 3, and beyond). Trial protocols mandate core-lab adjudication of TICI grade from blinded, standardized final-run angiograms, ensuring consistent application of the 0–3 (or extended 0–2c–3) scale across sites and operators.
Beyond trials, TICI grade is now a routine quality metric reported by comprehensive stroke centers, feeding into device selection research, operator training and credentialing, and ongoing refinement of thrombectomy technique — a single number, assessed at the end of a procedure that may last anywhere from 15 minutes to several hours, distilling the technical success of one of modern medicine's most time-critical interventions.